| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Center for Experimental Therapeutics and Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104; and
Division of Nephrology and Endocrinology, University of Tokyo School of Medicine, Tokyo, Japan
Renal ischemia-reperfusion injury (IRI) is a feature of ischemic acute renal failure and it impacts both short- and long-term graft survival after kidney transplantation. Complement activation has been implicated in renal IRI, but its mechanism of action is uncertain and the determinants of complement activation during IRI remain poorly understood. We engineered mice deficient in two membrane complement regulatory proteins, CD55 and CD59, and used them to investigate the role of these endogenous complement inhibitors in renal IRI. CD55-deficient (CD55-/-), but not CD59-deficient (CD59-/-), mice exhibited increased renal IRI as indicated by significantly elevated blood urea nitrogen levels, histological scores, and neutrophil infiltration. Remarkably, although CD59 deficiency alone was inconsequential, CD55/CD59 double deficiency greatly exacerbated IRI. Severe IRI in CD55-/-CD59-/- mice was accompanied by endothelial deposition of C3 and the membrane attack complex (MAC) and medullary capillary thrombosis. Complement depletion in CD55-/-CD59-/- mice with cobra venom factor prevented these effects. Thus, CD55 and CD59 act synergistically to inhibit complement-mediated renal IRI, and abrogation of their function leads to MAC-induced microvascular injury and dysfunction that may exacerbate the initial ischemic assault. Our findings suggest a rationale for anti-complement therapies aimed at preventing microvascular injury during ischemia reperfusion, and the CD55-/-CD59-/- mouse provides a useful animal model in this regard.
This article has been cited by other articles:
|
|
 |
|
  V. Pavlov, H. Raedler, S. Yuan, S. Leisman, W.-h. Kwan, P. N. Lalli, M. E. Medof, and P. S. Heeger Donor Deficiency of Decay-Accelerating Factor Accelerates Murine T Cell-Mediated Cardiac Allograft Rejection J. Immunol., October 1, 2008; 181(7): 4580 - 4589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zheng, X. Zhang, B. Feng, H. Sun, M. Suzuki, T. Ichim, N. Kubo, A. Wong, L. R. Min, M. E. Budohn, et al. Gene Silencing of Complement C5a Receptor Using siRNA for Preventing Ischemia/Reperfusion Injury Am. J. Pathol., October 1, 2008; 173(4): 973 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, Y. Kimura, C. Fang, L. Zhou, G. Sfyroera, J. D. Lambris, R. A. Wetsel, T. Miwa, and W.-C. Song Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo Blood, July 1, 2007; 110(1): 228 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Miwa, M. A. Maldonado, L. Zhou, K. Yamada, G. S. Gilkeson, R. A. Eisenberg, and W.-C. Song Decay-Accelerating Factor Ameliorates Systemic Autoimmune Disease in MRL/lpr Mice via Both Complement-Dependent and -Independent Mechanisms Am. J. Pathol., April 1, 2007; 170(4): 1258 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jha, J.-H. Sohn, Q. Xu, Y. Wang, H. J. Kaplan, P. S. Bora, and N. S. Bora Suppression of Complement Regulatory Proteins (CRPs) Exacerbates Experimental Autoimmune Anterior Uveitis (EAAU). J. Immunol., June 15, 2006; 176(12): 7221 - 7231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Devarajan Update on Mechanisms of Ischemic Acute Kidney Injury J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1503 - 1520. [Full Text] [PDF]
|
|
|
|
|
|
H. Patel, R. A.G. Smith, S. H. Sacks, and W. Zhou Therapeutic Strategy with a Membrane-Localizing Complement Regulator to Increase the Number of Usable Donor Organs after Prolonged Cold Storage J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1102 - 1111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Lidington, R. Steinberg, A. R. Kinderlerer, R. C. Landis, M. Ohba, A. Samarel, D. O. Haskard, and J. C. Mason A role for proteinase-activated receptor 2 and PKC-{epsilon} in thrombin-mediated induction of decay-accelerating factor on human endothelial cells Am J Physiol Cell Physiol, December 1, 2005; 289(6): C1437 - C1447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Louis, K. E. Hamilton, T. Kong, and S. P. Colgan HIF-dependent induction of apical CD55 coordinates epithelial clearance of neutrophils FASEB J, June 1, 2005; 19(8): 950 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Liu, T. Miwa, B. Hilliard, Y. Chen, J. D. Lambris, A. D. Wells, and W.-C. Song The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo J. Exp. Med., February 22, 2005; 201(4): 567 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Turnberg, M. Botto, M. Lewis, W. Zhou, S. H. Sacks, B. P. Morgan, M. J. Walport, and H. T. Cook CD59a Deficiency Exacerbates Ischemia-Reperfusion Injury in Mice Am. J. Pathol., September 1, 2004; 165(3): 825 - 832. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
